| P/E (FY) | — | Sales (TTM) | $3,000 |
| Earnings (TTM) | -$4.1M | ROE | −198.10% |
| Net Margin | −83520.00% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −88.04% |
| Market Cap | $46.4M | Trading Days | 1123 |
| 52W High | 4.59 |
| 52W Low | 1.67 |
| % Off High | −58.61% |
| YTD | −41.18% | 1Y | −36.67% |
| 3Y | −97.12% | Since incept. (ann.) | −61.26% |
| Ann. Volatility (1Y) | 85.63% | Ann. Volatility (3Y) | 137.56% |
| Sharpe (1Y) | −0.12 | Sharpe (3Y) | −0.18 |
| Max Drawdown (1Y) | −56.42% | Max Drawdown (3Y) | −97.97% |
| Beta (3Y, vs SPY) | 1.71 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MCRB | Seres Therapeutics, Inc. | $46.5M | 7.6 |
| IBO | IMPACT BIOMEDICAL INC. | $46.6M | — |
| BHST | BIOHARVEST SCIENCES INC. | $46.0M | — |
| GOSS | Gossamer Bio, Inc. | $46.8M | — |
| EDSA | Edesa Biotech, Inc. | $47.6M | — |
| RNXT | RenovoRx, Inc. | $43.5M | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $49.8M | — |
| FLNA | FILANA THERAPEUTICS, INC. | $43.0M | — |
| DWTX | Dogwood Therapeutics, Inc. | $51.5M | — |
| CTOR | CITIUS ONCOLOGY, INC. | $51.7M | — |
| XLO | Xilio Therapeutics, Inc. | $52.6M |
| RANI | Rani Therapeutics Holdings, Inc. | $53.6M | — |
